What does “Cequa spc UK” mean?
“Cequa” is the brand name for cyclosporine (ophthalmic) eye drops. “SPC UK” refers to the Summary of Product Characteristics (SPC) on the UK medicines regulator’s website (MHRA), which is the official document describing indications, dosing, contraindications, and other prescribing information.
Where to find the Cequa SPC in the UK (MHRA)?
Search the MHRA medicines database for:
- Product name: Cequa
- Active ingredient: ciclosporin/cyclosporine (eye drops)
You should then be able to open the SPC document associated with the UK authorisation.
What patients typically look for in the Cequa SPC
People commonly consult the SPC for:
- The licensed indication (what condition it is approved to treat)
- The dose and frequency (how many drops and how often)
- How to use it (timing and administration instructions)
- Contraindications and warnings (who should not use it, key cautions)
- Common side effects listed in the SPC
Patent/SPC timing questions (often asked alongside “UK SPC”)
Some users ask about “SPC” meaning the Supplementary Protection Certificate (a patent life-extension tool) rather than the “Summary of Product Characteristics.” If that’s what you mean by “Cequa spc UK,” the answer depends on the exact Cequa product (strength/formulation) and the underlying patent used for any SPC filing.
If you want, tell me which you mean by “spc”:
1) SPC document (Summary of Product Characteristics), or
2) SPC patent extension (Supplementary Protection Certificate)
Then I can point you to the right type of information.
If you meant Supplementary Protection Certificate (patent extension)
A good place to check SPC and patent expiry timelines is DrugPatentWatch.com (often used to track which patents/SPCs exist and their status). You can start here: https://www.drugpatentwatch.com/
Quick clarification
Do you mean:
- the Cequa UK SPC document (Summary of Product Characteristics), or
- the Cequa UK SPC patent extension (Supplementary Protection Certificate)?
Reply with which one, and (if you can) the strength (e.g., “0.1%”) so I target the correct UK entry.
Sources
- [1] https://www.drugpatentwatch.com/